Pelosof, L., Saung, M. T., Donoghue, M., Casak, S., Mushti, S., Cheng, J., . . . Fashoyin‐Aje, L. (2021). Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy. Oncologist.
Citação norma ChicagoPelosof, Lorraine, et al. "Benefit–Risk Summary of Nivolumab for the Treatment of Patients With Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy." Oncologist 2021.
Citação norma MLAPelosof, Lorraine, et al. "Benefit–Risk Summary of Nivolumab for the Treatment of Patients With Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy." Oncologist 2021.